2018-07-16 |
1 |
Complaint |
mg, prior
to expiration of U.S. Patent No. 9,187,405 (“the ’405 patent”).
…1. This is an action for patent infringement arising under the patent laws of
the United States, …)(IV), with respect to the ’405 patent asserting that the ’405
patent is invalid, unenforceable, and/…)(IV), with respect to the ’405 patent asserting that the ’405
patent is invalid, unenforceable, and/…)(IV), with respect to the ’405 patent asserting that the
’405 patent is invalid, unenforceable, and/ |
External link to document |
2018-11-05 |
237 |
Stipulation |
alleging infringement of U.S. Patent No. 9,187,405
(“the ’405 patent”) based on Apotex’s submission …of the ’405 patent before the Patent Trials and Appeals Board;
WHEREAS, the Patent Trial and Appeal…regarding the validity, patentability, or unenforceability of the ’405
patent. Upon entry of the last…regarding the validity, patentability, or unenforceability of the ’405 patent. Any judgment or
determination…regarding the validity, patentability, or unenforceability of the ’405 patent,
then either Party may |
External link to document |
2018-12-12 |
293 |
Notice of Service |
Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm … 16 July 2018
1:18-cv-01043
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
2019-02-13 |
354 |
Notice of Service |
Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing… 16 July 2018
1:18-cv-01043
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
2019-02-20 |
392 |
Notice of Service |
of Invalidity References Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing…
16 July 2018
1:18-cv-01043
Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
2018-07-16 |
4 |
Patent/Trademark Report to Commissioner |
the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405. (nmg) (Entered: 07… 16 July 2018
1:18-cv-01043
835 Patent - Abbreviated New Drug Application(ANDA)
Defendant |
External link to document |
2019-04-16 |
470 |
Redacted Document |
U.S. Patent No. 8,324,283) invalidated at the Patent Office.
Novartis uses the pending loss of protection…earliest-expiring patent, U.S. Patent No. 5,604,229 (“’229 patent”) through
appeal, with its formulation patent (U.…inventors applied for the patent-in-suit, U.S. Patent No. 9,187,405 (“’405 patent”), the details of
Novartis… THE PATENT-IN-SUIT (U.S. PATENT NO. 9,187,405).
Novartis listed four patents in FDA’s …submitted ANDAs with patent certifications to other patents before the ’405
patent was listed in FDA’s |
External link to document |